This website is intended for UK healthcare professionals only Log in | Register

Tag Archives: intravitreal pegaptanib sodium

January 2009 Br J Cardiol 2009;16(Suppl 2):S14-S15

Efficacy and safety of intravitreal pegaptanib sodium in the treatment of neovascular age-related macular degeneration

Sobha Sivaprasad, John J Wroblewski

Abstract

Efficacy The Vascular Endothelial Growth Factor Inhibition Study in Ocular Neovascularization (VISION) trial showed that 70% of patients with wet AMD treated for 12 months with six-weekly pegaptanib sodium responded to treatment (lost <15 letters). This compared with only 55% of control (sham) subjects. Furthermore, 6% of patients receiving pegaptanib experienced an improvement in their vision (gained ≥15 letters).2 In a retrospective analysis performed to acquire data on ‘real-life’ experience with pegaptanib, data were collected from 164 patients with any angiographic subtype of sub-foveal choroidal neovascularisation secondary to

| Full text

For healthcare professionals only

Add Banner

Close

You are not logged in

You need to be a member to print this page.
Find out more about our membership benefits

Register Now Already a member? Login now
Close

You are not logged in

You need to be a member to download PDF's.
Find out more about our membership benefits

Register Now Already a member? Login now